Diabetic Retinopathy Market forecast
The Diabetic Retinopathy Market forecast projects a significant growth trajectory, with the market expected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% between 2025 and 2032. This trajectory is driven by the unrelenting rise in the global diabetic population, which serves as the primary risk factor for diabetic retinopathy. The forecast takes into account not only the increasing number of diagnosed cases but also the growing awareness of the disease and its complications, which is leading to earlier detection and intervention. The market is forecasted to increase from its $9.91 billion valuation in 2025 to an estimated $15.40 billion by 2032.
The forecast for the diabetic retinopathy market also includes a detailed breakdown by treatment type and geographical region. It predicts that anti-VEGF drug therapy will continue to dominate the treatment segment, owing to its superior clinical benefits and established efficacy as a first-line treatment for diabetic macular edema and proliferative diabetic retinopathy. The forecast also anticipates a surge in demand for AI-enabled diagnostic tools and telemedicine platforms, which will facilitate remote screening and improve access to care, especially in underserved areas. Geographically, while North America is projected to maintain its market leadership due to its advanced healthcare infrastructure and high healthcare expenditure, the Asia-Pacific region is forecasted to exhibit the highest growth rate, fueled by its large patient pool and improving healthcare access.